2016 American Transplant Congress
Evolving to Everolimus: A Safe and Effective Option for Pancreas Transplant.
University of Utah Health Care, Salt Lake City, UT.
Although everolimus is an attractive option for conversion therapy in pancreas tx pts that experience SE's of commonly used immunosuppression, TAC and MPA, there is…2016 American Transplant Congress
Relationship Between Clinical Events and Everolimus Exposure at 12 Months in De Novo Renal Transplant Recipients.
We assessed the incidence of post-transplant biopsy-proven acute rejection (BPAR), graft loss and other adverse events (AEs) associated with everolimus (EVR) and tacrolimus (TAC) exposure…2016 American Transplant Congress
In Their Own Words: Living Kidney Donors Who Develop Kidney Failure.
Background: Psychosocial data about living kidney donation have been collected for almost five decades. The results are almost uniformly positive, even in the early years…2016 American Transplant Congress
Everolimus versus Mycophenolate Mofetil in Combination with Tacrolimus: A Propensity Score Matching Analysis in Liver Transplantation.
Background: No trial has so far investigated everolimus (EVR)-incorporating immunosuppressive regimens versus combined use of tacrolimus (TAC) and mycophenolate mofetil (MMF) in liver transplantation (LT).Materials…2016 American Transplant Congress
Pre-Transplant Intra-Arterial Liver Directed Therapy Does Not Increase the Risk of Hepatic Arterial Misadventures in Liver Transplantation.
Background: Pretransplant liver directed therapy has emerged as standard of care for patients with end stage liver disease complicated by unresectable hepatocellular cancer. The aim…2016 American Transplant Congress
Earlier Repletion of Lymphocytes After Alemtuzumab Induction Is Associated with a Lower Incidence of Infection Following Renal Transplantation.
Imperial College Renal and Transplant Centre, Hammersmith Hospital, London, United Kingdom.
Introduction: Alemtuzumab has been increasingly used as an induction agent in renal transplantation, although the optimal dose is unknown. We have previously reported that alemtuzumab…2016 American Transplant Congress
Chemoprevention of Cutaneous Squamous Cell Carcinoma in Renal Transplant Recipients: A Case-Controlled Analysis.
Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom.
Organ transplant recipients are up to 200 times more likely to develop cutaneous squamous cell carcinoma (SCC) than age-matched general populations. Systemic retinoids, such as…2016 American Transplant Congress
A Novel Inflammation-Targeting Tacrolimus Hydrogel for Liver Transplantation.
Background:Immunosuppressant have played a critical role for improving graft survival after liver transplantation (LT). While long-term systemic use of immunosuppressant such as tacrolimus (FK506) is…2016 American Transplant Congress
A Prospective Randomized, Comparative Trial of High-Dose Mizoribine versus Mycophenolate Mofetil in Combination with Tacrolimus and Basiliximab for Living Donor Renal Transplantation: A Multi-Center Trial.
PURPOSE: To compare the clinical outcomes of mizoribine (MZR; 12 mg/kg/day) and mycophenolate mofetil (MMF; 2000 mg/day) in combination with tacrolimus (FK), basiliximab (SIM), and…2016 American Transplant Congress
Telemedicine to Reduce Readmissions Post Liver Transplant: Compliance and Feasibility Results.
Telemedicine (TM) was added to our care model as a mechanism to reduce readmissions post liver transplant (LTx). Establishing a TM home allows for remote…
American Transplant Congress abstracts